Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 303

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Formatted anti–tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen‐induced arthritis

Coppieters, Ken, Dreier, Torsten, Silence, Karen, Haard, Hans De, Lauwereys, Marc, Casteels, Peter, Beirnaert, Els, Jonckheere, Heidi, Wiele, Christophe Van De, Staelens, Ludovicus, Hostens, Jeroen, Revets, Hilde, Remaut, Erik, Elewaut, Dirk, Rottiers, Pieter · 2006 · Arthritis & Rheumatism

Abstract

Objective: The advent of tumor necrosis factor (TNF)–blocking drugs has provided rheumatologists with an effective, but highly expensive, treatment for the management of established rheumatoid arthritis (RA). Our aim was to explore preclinically the application of camelid anti‐TNF VHH proteins, which are single‐domain antigen binding (VHH) proteins homologous to human immunoglobulin V H domains, as TNF antagonists in a mouse model of RA. Methods: Llamas were immunized with human and mouse TNF, and antagonistic anti‐TNF VHH proteins were isolated and cloned for bacterial production. The resulting anti‐TNF VHH proteins were recombinantly linked to yield bivalent mouse and human TNF‐specific molecules. To increase the serum half‐life and targeting properties, an anti–serum albumin anti‐TNF VHH domain was incorporated into the bivalent molecules. The TNF‐neutralizing potential was analyzed in vitro. Mouse TNF‐specific molecules were tested in a therapeutic protocol in murine collagen‐induced arthritis (CIA). Disease progression was evaluated by clinical scoring and histologic evaluation. Targeting properties were evaluated by 99m Tc labeling and gamma camera imaging. Results: The bivalent molecules were up to 500 times more potent than the monovalent molecules. The antagonistic potency of the anti‐human TNF VHH proteins exceeded even that of the anti‐TNF antibodies infliximab and adalimumab that are used clinically in RA. Incorporation of binding affinity for albumin into the anti‐TNF VHH protein significantly prolonged its serum half‐life and promoted its targeting to inflamed joints in the murine CIA model of RA. This might explain the excellent therapeutic efficacy observed in vivo. Conclusion: These data suggest that because of the flexibility of their format, camelid anti‐TNF VHH proteins can be converted into potent therapeutic agents that can be produced and purified cost‐effectively.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.21827

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Cited by

See all 303

Metadata

Authors
Coppieters, K., Dreier, T., Silence, K., Haard, H. D., Lauwereys, M., Casteels, P., Beirnaert, E., Jonckheere, H., Wiele, C. V. D., Staelens, L., Hostens, J., Revets, H., Remaut, E., Elewaut, D., & Rottiers, P.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2006-05-30
Volume
54
Issue
6
Pages
1856-1866
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2079379157
Cited by
303
References
41
FWCI
8.56
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Formatted anti–tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen‐induced arthritis. https://app.cochat.ai/papers/10.1002/art.21827
The paper
Coppieters, K., Dreier, T., Silence, K., Haard, H. D., Lauwereys, M., Casteels, P., Beirnaert, E., Jonckheere, H., Wiele, C. V. D., Staelens, L., Hostens, J., Revets, H., Remaut, E., Elewaut, D., & Rottiers, P. (2006). Formatted anti–tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen‐induced arthritis. Arthritis & Rheumatism. https://doi.org/10.1002/art.21827

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.